%0 Journal Article
%T Targeting  ErbB2  aberrations in non-small cell lung cancer
%A Ge, Xuan
%A Tariq, Sara
%A Cheng, Haiying
%A Halmos, Balazs
%J Precision Cancer Medicine
%D 2019
%B 2019
%9 
%! Targeting  ErbB2  aberrations in non-small cell lung cancer
%K 
%X Human epidermal growth factor 2 ( HER2  or  ErbB2 ) mutations in lung cancer are oncogenic drivers similar to epidermal growth factor receptor ( EGFR ) mutations in non-small cell lung cancers. Until recently,  ErbB2 -mutant lung cancers have generally been resistant to various targeted agents. However, a new wave of  ErbB2 -targeting drugs has shown promise for this subset. We highlight a case of a patient with an  ErbB2 -mutant lung cancer with an exon 20 YVMA insertion who had a good response to poziotinib and review the current literature on the methods of testing for  ErbB2  mutations and the efficacy of various known and emerging targeted agents.
%U https://pcm.amegroups.org/article/view/5169
%V 2
%P 
%@ 2617-2216